MedPath

Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin

Not Applicable
Completed
Conditions
Atopic Dermatitis
Interventions
Other: P927 - LICHTENA DermAD CREMA CORPO
Registration Number
NCT03484897
Lead Sponsor
Derming SRL
Brief Summary

Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with positive anamnesis for atopy and habitual itching.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Adult volunteers of both sexes
  • volunteers with positive anamnesis for atopy and habitual itching
  • volunteers in a good general state of health in the Investigator opinion
  • negative pregnancy test (only for female subjects not in menopause)
  • accepting to follow the instructions received by the investigator
  • accepting to not change their habits regarding food, physical activity, body cleansing
  • agreeing not to apply or take any product/drug or use body massages able to change skin conditions during the entire duration of the study
  • accepting not to expose their face to strong UV irradiation (UV session, or sun bathes), during the entire duration of the study
  • no participation in a similar study currently or during the previous 3 months
  • volunteers who are giving a written informed consent.
Exclusion Criteria
  • Pregnancy (only for female subjects not in menopause)
  • lactation (only for female subjects not in menopause)
  • change in the normal habits in the last month
  • participation in a similar study during the previous 3 months
  • known allergy to one or several ingredients of the product on trial
  • insufficient adhesion to the study protocol
  • Dermatitis
  • presence of cutaneous disease on the tested area, as lesions, scars, malformations
  • clinical and significant skin condition on the test area.
  • Diabetes
  • endocrine disease
  • hepatic disorder
  • renal disorder
  • cardiac disorder
  • pulmonary disease
  • cancer
  • neurological or psychological disease
  • inflammatory/immunosuppressive disease
  • drug allergy.
  • Anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago)
  • using of drugs able to influence the test results in the investigator opinion.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
P927 - LICHTENA DermAD CREMA CORPOP927 - LICHTENA DermAD CREMA CORPOApplication of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
Primary Outcome Measures
NameTimeMethod
Change from baseline of Transepidermal water loss (TEWL)Baseline (T0), 1 month (T1), 2 months (T2)

The measurement of TEWL, performed by the use of Tewameter® TM300, allows to objectively monitor skin responses to cosmetic treatments. A shift from low-normal rates of TEWL to high levels is due to barrier disruption.

Change from baseline of Superficial skin hydrationBaseline (T0), 1 month (T1), 2 months (T2)

Skin electrical capacitance value is measured with Corneometer CM825

Change from baseline of Deep skin hydrationBaseline (T0), 1 month (T1), 2 months (T2)

Tissue dielectric constant of deep skin layers is measured with MoistureMeterD

Change from baseline of Surface microrelief's regularityBaseline (T0), 1 month (T1), 2 months (T2)

Surface microrelief's regularity is performed on skin replicas images acquired by Primos

Change from baseline of Epicutaneous pHBaseline (T0), 1 month (T1), 2 months (T2)

Surface cutaneous pH is measured with pH meter HI5221

Secondary Outcome Measures
NameTimeMethod
Change from baseline of itching sensationBaseline (T0), 1 month (T1), 2 months (T2)

Each volunteers scored its own itching sensation thanks to a visual analogic scale (VAS from 0 = no itching to 10= strong itching).

Trial Locations

Locations (1)

DERMING

🇮🇹

Milano, MI, Italy

© Copyright 2025. All Rights Reserved by MedPath